公开(公告)号：US12048691B2

公开(公告)日：2024-07-30

申请号：US17525619

申请日：2021-11-12

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Akash Jain ,  Ching-Kuo Jim Chow

IPC: A61K9/20 ,  A61K31/427 ,  A61P31/04

CPC classification number: A61K31/427 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2054 ,  A61P31/04

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

公开(公告)号：US20250049766A1

公开(公告)日：2025-02-13

申请号：US18665330

申请日：2024-05-15

Applicant: Spero Therapeutics, Inc.

Inventor： Akash Jain ,  Ching-Kuo Jim Chow

IPC: A61K31/427 ,  A61K9/20 ,  A61P31/04

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.